DOD Reconstructive Transplant, Advanced Technology Development Award | HT9425 23 RTRP ATDA

Opportunity Information: Apply for HT9425 23 RTRP ATDA

The DOD Reconstructive Transplant, Advanced Technology Development Award (FY23 RTRP ATDA; opportunity number HT9425 23 RTRP ATDA) is a Department of Defense funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that supports science and technology research aimed at moving reconstructive transplantation innovations from strong preclinical results toward real-world, deployable products. The core purpose is translation: taking something that already has proof-of-concept or an early prototype and advancing it through the kind of rigorous, reproducible development work needed to set up the next step, such as clinical trials or another defined development milestone. The mechanism is offered as a cooperative agreement or grant, categorized under CFDA 12.420, and eligibility is listed as unrestricted, meaning many organization types can apply as long as they meet any additional eligibility language in the full announcement.

A major emphasis of this award is on study design and feasibility. Applicants are expected to lay out a clear, well-integrated experimental plan that is methodologically strong and built for reproducibility, with enough detail to show the work can actually be executed and will generate interpretable results. Where statistics apply, the application should include a statistical plan and appropriate power analysis, rather than treating statistics as an afterthought. Reviewers are looking for a development-ready approach, so the design should not only test a hypothesis, but also intentionally position the product to advance into its next development phase. In other words, the project should be engineered to reduce the typical risks that stall translation (uncertain feasibility, weak rigor, unclear endpoints, inconsistent methods, or insufficient planning for scale-up and next-step validation).

Military relevance and impact are also central. The research has to connect directly to the needs of military Service Members and/or Veterans recovering from traumatic injury, and it should also consider the practical needs of those who support them, including family members, caregivers, and clinicians. Applicants are expected to describe both short-term and long-term impact in a straightforward way: what the product will change, how it will improve outcomes or care delivery, and why this matters specifically in the context of traumatic injury and reconstructive transplantation. Projects must align with at least one of the program’s specified focus areas (referenced in the notice as the FY22 RTRP Advanced Technology Development Award Focus Areas). While working with military or VA researchers and clinicians is encouraged and can strengthen the practical relevance of the project, it is not presented as a strict requirement.

A required element is a transition plan, described as a post-award Transition Plan (Attachment 9). This is where applicants must show they are not stopping at a promising set of results, but actively planning for what comes next after the award ends. The transition plan should identify plausible next sources of funding and resources and explain the concrete pathway for advancing the product to the next level of development, such as preparing for clinical evaluation, meeting regulatory milestones, or moving toward delivery in military and/or civilian healthcare markets. If the product being developed has regulatory implications (for example, a device, biologic, or combination product), the application should include a regulatory strategy that demonstrates awareness of the approval or clearance environment and shows how regulatory requirements will be addressed as development continues.

The award also expects applicants to come in with meaningful preliminary data. This is not meant for brand-new, untested ideas; there should already be proof-of-concept evidence that the proposed product could be useful, or there should be a prototype or preliminary version of the product in hand. The application should include preliminary and/or published data that supports the scientific rationale and relevance to reconstructive transplantation. Those data can be unpublished if they come from the proposing team, and they can also draw on published literature, but the overall message has to be that the work is ready to be advanced rather than discovered from scratch.

Finally, the program explicitly notes that it is acceptable to leverage novel findings from solid organ transplantation research and test them in a vascularized composite allotransplantation (VCA) context, as long as the applicant clearly justifies why that translation is scientifically and clinically meaningful. The proposal should explain whether results might differ in VCA compared to solid organ settings, why confirming similarity matters, or how repeating or adapting the work for VCA could reveal new mechanisms or unique aspects of VCA biology and clinical management. This signals that the program is open to cross-pollination from related transplant fields, but only when the rationale is clear and the expected benefit to reconstructive transplantation is convincingly explained.

Key logistics included in the listing note that the opportunity was posted June 5, 2023, with an original closing date of October 11, 2023, and an expectation of approximately three awards. The award ceiling is shown as 0 in the listing, which typically means applicants need to consult the full announcement for budget limits or that the ceiling is not specified in that particular summary field. Overall, the opportunity is structured for teams that already have a credible foundation and are ready to do the hard translational work: rigorous development studies, clear relevance to military trauma recovery, and a believable plan to move the product into the next stage beyond the grant.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Reconstructive Transplant, Advanced Technology Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 05, 2023.
• Applicants must submit their applications by Oct 11, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 RTRP ATDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: